This report describes and evaluates the global influenza diagnostics market. It covers 2016-2021, termed the historic period, and 2021-2026 termed the forecast period, along with further forecasts for the period 2026-2031.
The global influenza diagnostics market reached a value of nearly $2,269.5 million in 2021, having increased at a compound annual growth rate (CAGR) of 16.5% since 2016. The market is expected to grow from $2,269.5 million in 2021 to $3,154.6 million in 2026 at a rate of 6.8%. The market is then expected to grow at a CAGR of 6.8% from 2026 and reach $4,374.5 million in 2031.
Growth in the historic period resulted from a rise in initiatives towards influenza, increased healthcare expenditure, rising air pollution levels, strong economic growth in emerging markets and increased aging population. Factors that negatively affected growth in the historic period were low healthcare access.
Going forward, a rise in healthcare expenditure, a rise in healthcare expenditure, increasing government support and increasing FDA approvals for influenza testing will drive market growth. Factors that could hinder the growth of the influenza diagnostics market in the future include a rise in interest rates, lack of healthcare infrastructure and false results.
The influenza diagnostics market is segmented by traditional diagnostic tests into rapid influenza diagnostics tests (RIDT), viral culture, DFA, serological assays, other traditional diagnostic tests. The rapid influenza diagnostics tests (RIDT) market was the largest segment of the influenza diagnostic market segmented by traditional diagnostic tests, accounting for 40.1% of the total in 2021 and viral culture segment is expected to be the fastest growing segment going forward, at a CAGR of 7.1% during 2021-2026.
The influenza diagnostic market is segmented by molecular diagnostic tests into reverse transcription polymerase chain reaction (RT-PCR), isothermal nucleic acid amplification tests (INAAT), loop mediated isothermal based amplification assays, transcription mediated isothermal based amplification assays, other isothermal nucleic acid amplification tests, others. The reverse transcription polymerase chain reaction (RT-PCR) market was the largest segment of the influenza diagnostic market segmented by molecular diagnostic tests, accounting for 35.9% of the total in 2021 and is expected to be the fastest growing segment going forward, at a CAGR of 7.2% during 2021-2026.
The influenza diagnostic market is segmented by end user into hospitals and clinical laboratories, diagnostic reference laboratories, academic/research institutes, other end users. The hospitals and clinical laboratories market was the largest segment of the influenza diagnostic market segmented by end user, accounting for 42.6% of the total in 2021 and diagnostic reference laboratories segment is expected to be the fastest growing segment going forward, at a CAGR of 7.1% during 2021-2026.
North America was the largest region in the global influenza diagnostic market, accounting for 34.1% of the total in 2021. It was followed by Asia Pacific, Western Europe, and then the other regions. Going forward, the fastest-growing regions in the influenza diagnostic market will be South America and Asia Pacific, where growth will be at CAGRs of 8.3% and 7.4% respectively. These will be followed by North America and Western Europe, where the markets are expected to grow at CAGRs of 6.6% and 6.5% respectively, during 2021-2026.
The influenza diagnostic market is highly fragmented, with a large number of small players. The top ten competitors in the market made up to 43.74% of the total market in 2020. Major players in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company, Thermo Fisher Scientific Inc, Quidel Corp, Danaher Corporation (Cepheid), Hologic Inc, DiaSorin S.p.A, GenMark Diagnostics, Inc and bioMerieux SA.
The top opportunities in the influenza diagnostic market segmented by traditional diagnostic tests will arise in the rapid influenza diagnostic tests (RIDT) segment, which will gain $347.4 million of global annual sales by 2026. The top opportunities in the influenza diagnostic market segmented by molecular diagnostic tests will arise in the reverse transcription polymerase chain reaction (RT-PCR) segment, which will gain $337.2 million of global annual sales by 2026. The top opportunities in the influenza diagnostic market segmented by end user will arise in the hospitals & clinical laboratories segment, which will gain $364.2 million of global annual sales by 2026. The influenza diagnostic market size will gain the most in the USA at $261.7 million.
Market-trend-based strategies for the influenza diagnostic market include strategic partnerships and acquisitions, use of artificial intelligence, collaborations between governments and manufacturers, at-home test kits, supportive government funding and initiatives.
Player-adopted strategies in the influenza diagnostic market include to focus on strengthening business by new product launches, focus on strengthening business globally and accelerate growth and expanding product portfolio by strategic partnership with companies.
To take advantage of the opportunities, the publisher reccomends the influenza diagnostics companies to focus on smartphone diagnostic apps, focus on expansion through collaborations, focus on technological improvement, establish operations in emerging markets, leverage growth in online sales post COVID-19, provide competitively priced offerings in low-income countries, focus on partnerships with end-users, leverage social media to maximize reach and focus on hospitals and other diagnostic centers.
The global influenza diagnostics market reached a value of nearly $2,269.5 million in 2021, having increased at a compound annual growth rate (CAGR) of 16.5% since 2016. The market is expected to grow from $2,269.5 million in 2021 to $3,154.6 million in 2026 at a rate of 6.8%. The market is then expected to grow at a CAGR of 6.8% from 2026 and reach $4,374.5 million in 2031.
Growth in the historic period resulted from a rise in initiatives towards influenza, increased healthcare expenditure, rising air pollution levels, strong economic growth in emerging markets and increased aging population. Factors that negatively affected growth in the historic period were low healthcare access.
Going forward, a rise in healthcare expenditure, a rise in healthcare expenditure, increasing government support and increasing FDA approvals for influenza testing will drive market growth. Factors that could hinder the growth of the influenza diagnostics market in the future include a rise in interest rates, lack of healthcare infrastructure and false results.
The influenza diagnostics market is segmented by traditional diagnostic tests into rapid influenza diagnostics tests (RIDT), viral culture, DFA, serological assays, other traditional diagnostic tests. The rapid influenza diagnostics tests (RIDT) market was the largest segment of the influenza diagnostic market segmented by traditional diagnostic tests, accounting for 40.1% of the total in 2021 and viral culture segment is expected to be the fastest growing segment going forward, at a CAGR of 7.1% during 2021-2026.
The influenza diagnostic market is segmented by molecular diagnostic tests into reverse transcription polymerase chain reaction (RT-PCR), isothermal nucleic acid amplification tests (INAAT), loop mediated isothermal based amplification assays, transcription mediated isothermal based amplification assays, other isothermal nucleic acid amplification tests, others. The reverse transcription polymerase chain reaction (RT-PCR) market was the largest segment of the influenza diagnostic market segmented by molecular diagnostic tests, accounting for 35.9% of the total in 2021 and is expected to be the fastest growing segment going forward, at a CAGR of 7.2% during 2021-2026.
The influenza diagnostic market is segmented by end user into hospitals and clinical laboratories, diagnostic reference laboratories, academic/research institutes, other end users. The hospitals and clinical laboratories market was the largest segment of the influenza diagnostic market segmented by end user, accounting for 42.6% of the total in 2021 and diagnostic reference laboratories segment is expected to be the fastest growing segment going forward, at a CAGR of 7.1% during 2021-2026.
North America was the largest region in the global influenza diagnostic market, accounting for 34.1% of the total in 2021. It was followed by Asia Pacific, Western Europe, and then the other regions. Going forward, the fastest-growing regions in the influenza diagnostic market will be South America and Asia Pacific, where growth will be at CAGRs of 8.3% and 7.4% respectively. These will be followed by North America and Western Europe, where the markets are expected to grow at CAGRs of 6.6% and 6.5% respectively, during 2021-2026.
The influenza diagnostic market is highly fragmented, with a large number of small players. The top ten competitors in the market made up to 43.74% of the total market in 2020. Major players in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company, Thermo Fisher Scientific Inc, Quidel Corp, Danaher Corporation (Cepheid), Hologic Inc, DiaSorin S.p.A, GenMark Diagnostics, Inc and bioMerieux SA.
The top opportunities in the influenza diagnostic market segmented by traditional diagnostic tests will arise in the rapid influenza diagnostic tests (RIDT) segment, which will gain $347.4 million of global annual sales by 2026. The top opportunities in the influenza diagnostic market segmented by molecular diagnostic tests will arise in the reverse transcription polymerase chain reaction (RT-PCR) segment, which will gain $337.2 million of global annual sales by 2026. The top opportunities in the influenza diagnostic market segmented by end user will arise in the hospitals & clinical laboratories segment, which will gain $364.2 million of global annual sales by 2026. The influenza diagnostic market size will gain the most in the USA at $261.7 million.
Market-trend-based strategies for the influenza diagnostic market include strategic partnerships and acquisitions, use of artificial intelligence, collaborations between governments and manufacturers, at-home test kits, supportive government funding and initiatives.
Player-adopted strategies in the influenza diagnostic market include to focus on strengthening business by new product launches, focus on strengthening business globally and accelerate growth and expanding product portfolio by strategic partnership with companies.
To take advantage of the opportunities, the publisher reccomends the influenza diagnostics companies to focus on smartphone diagnostic apps, focus on expansion through collaborations, focus on technological improvement, establish operations in emerging markets, leverage growth in online sales post COVID-19, provide competitively priced offerings in low-income countries, focus on partnerships with end-users, leverage social media to maximize reach and focus on hospitals and other diagnostic centers.
Table of Contents
1. Influenza Diagnostics Market Executive Summary2. Table of Contents3. List of Figures4. List of Tables5. Report Structure
6. Introduction
7. Influenza Diagnostics Market Characteristics
8. Influenza Diagnostics Market Trends And Strategies
9. Impact Of COVID-19 On Influenza Diagnostics Market
10. Global Influenza Diagnostics Market Size And Growth
11. Global Influenza Diagnostics Market Segmentation
12. Influenza Diagnostics Market, Regional And Country Analysis
13. Asia-Pacific Influenza Diagnostics Market
14. Western Europe Influenza Diagnostics Market
15. Eastern Europe Influenza Diagnostics Market
16. North America Influenza Diagnostics Market
17. South America Influenza Diagnostics Market
18. Middle East Influenza Diagnostics Market
19. Africa Influenza Diagnostics Market
20. Influenza Diagnostics Market Competitive Landscape And Company Profiles
21. Key Mergers And Acquisitions In The Influenza Diagnostics Market
22. Influenza Diagnostics Market Opportunities And Strategies
23. Influenza Diagnostics Market, Conclusions And Recommendations
24. Appendix
Executive Summary
Influenza Diagnostics Global Market Opportunities And Strategies To 2031 provides the strategists; marketers and senior management with the critical information they need to assess the global influenza diagnostics market as it emerges from the COVID-19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description:
Where is the largest and fastest growing market for influenza diagnostics? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The influenza diagnostics market global report answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider influenza diagnostics market; and compares it with other markets.
The report covers the following chapters
- Executive Summary - The executive summary section of the report gives a brief overview and summary of the report.
- Report Structure - This section gives the structure of the report and the information covered in the various sections.
- Introduction - This section gives the segmentation of the influenza diagnostics market by geography, by traditional diagnostic tests, by molecular diagnostic tests and by end user covered in this report.
- Market Characteristics - The market characteristics section of the report defines and explains influenza diagnostics market. This chapter also defines and describes goods and related services covered in the report.
- Trends And Strategies - This chapter describes the major trends shaping the global influenza diagnostics market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
- Impact of COVID-19 - This section describes the impact of COVID-19 on the influenza diagnostics market.
- Global Market Size And Growth - This section contains the global historic (2016-2021) and forecast (2021-2026, 2031) market values, and drivers and restraints that support and restrain the growth of the market in the historic and forecast periods.
- Regional Analysis - This section contains the historic (2016-2021), forecast (2021-2026, 2031) market value and growth and market share comparison by region.
- Segmentation - This section contains the market values (2016-2021, 2021-2026, 2031) and analysis for different segments in the market.
- Regional Market Size and Growth - This section contains the region’s market size (2021), historic and forecast (2021-2026, 2031) market values, and growth and market share comparison of major countries within the region. This report includes information on all the regions (Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa).
- Competitive Landscape - This section covers details on the competitive landscape of the global influenza diagnostics market, estimated market shares and company profiles for the leading players.
- Key Mergers And Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities And Strategies - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
- Conclusions And Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for influenza diagnostics providers in terms of product/service offerings, geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Scope
Markets Covered:
- By Traditional Diagnostic Tests: Rapid Influenza Diagnostics Tests (RIDT); Viral Culture; DFA; Serological Assays; Other Traditional Diagnostic Tests
- By Molecular Diagnostic Tests: Reverse Transcription Polymerase Chain Reaction (RT-PCR); Isothermal Nucleic Acid Amplification Tests (INAAT); Loop Mediated Isothermal Based Amplification Assays; Transcription Mediated Isothermal Based Amplification Assays; Other Isothermal Nucleic Acid Amplification Tests; Other Molecular Diagnostic Tests
- By End User: Hospitals And Clinical Laboratories; Diagnostic Reference Laboratories; Academic/Research Institutes; Other End Users
Companies Mentioned:
Abbott Laboratories; F. Hoffmann-La Roche Ltd.; Becton, Dickinson and Company; Thermo Fisher Scientific Inc.; Quidel Corp
Countries:
China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia
Regions:
Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series:
Five years historic and ten years forecast.
Data:
Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; influenza diagnostics indicators comparison.
Data segmentations:
country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing:
Data and analysis throughout the report is sourced using end notes.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- Becton, Dickinson and Company
- Thermo Fisher Scientific Inc
- Quidel Corp
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 302 |
| Published | July 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 2269.5 Million |
| Forecasted Market Value ( USD | $ 4374.5 Million |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
